- Home
- GGAL vs PCVX Comparison
GGAL vs PCVX Comparison
Compare GGAL & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGAL | PCVX |
|---|---|---|
| Founded | 1905 | 2013 |
| Country | Argentina | United States |
| Employees | 10079 | 507 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GGAL | PCVX |
|---|---|---|
| Price | $40.99 | $52.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $69.00 | ★ $88.25 |
| AVG Volume (30 Days) | 1.0M | ★ 1.3M |
| Earning Date | 03-07-2023 | 05-07-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $62.29 | N/A |
| Revenue Next Year | $22.88 | N/A |
| P/E Ratio | $13.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.89 | $29.10 |
| 52 Week High | $65.48 | $65.00 |
Technical Indicators
Market Signals| Indicator | GGAL | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 38.76 | 36.95 |
| Support Level | $39.97 | $52.04 |
| Resistance Level | $45.01 | $56.04 |
| Average True Range (ATR) | 1.87 | 2.51 |
| MACD | -0.07 | -0.51 |
| Stochastic Oscillator | 28.25 | 33.53 |
Price Performance
Historical ComparisonAbout GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.